key: cord-0318261-0ho38ugk
authors: Lovetrue, B.; Lovetrue, I.
title: Prospectively validated disease-agnostic predictive medicine with hybrid AI
date: 2022-03-15
journal: nan
DOI: 10.1101/2022.03.14.22272372
sha: 3938e017cf711cec6f91d072c5f7a0795c3f11c0
doc_id: 318261
cord_uid: 0ho38ugk

Despite numerous superhuman achievements in complex challenges, standalone AI does not free life science from the long-term bottleneck of linearly extracting new knowledge from exponentially growing new data, severely limiting the success rate of drug discovery. Inspired by the state-of-the-art AI training methods, we trained a human-centric hybrid augmented intelligence (HAI) to learn a foundation model6 that extracts all-encompassing knowledge of human physiology and diseases. To evaluate the quality of HAI's extracted knowledge, we designed the public, prospective prediction of pivotal ongoing clinical trial outcomes at large scale (PROTOCOLS) challenge to benchmark HAI's real-world performance of predicting drug clinical efficacy without access to human data. HAI achieved a 10.5-fold improvement from the baseline with 99% confidence in the PROTOCOLS validation, readily increasing the average clinical success rate of investigational new drugs from 7.9% to 90% for almost any human diseases. The validated HAI confirms that exponentially extracted knowledge alone is sufficient for accurately predicting drug clinical efficacy, effecting a total reversal of Eroom's aw. HAI is also the world's first clinically validated model of human aging that could substantially speed up the discovery of preventive medicine for all age-related diseases. Our results demonstrate that disruptive breakthroughs necessitate the smallest team size to attain the largest HAI for optimal knowledge extraction from high-dimensional low-quality data space, thus establishing the first prospective proof of the previous discovery that small teams disrupt. The global adoption of training HAI provides a well-beaten economic path to mass-produce scientific and technological breakthroughs via exponential knowledge extraction and better designs of data labels for training better performing AI.

(BNNs) are good at learning knowledge from the low-dimensional space of low-quality data. As a result, neither ANNs nor BNNs alone are suitable for improving the efficiency of knowledge extraction from life science data.

The multi-faceted correspondence between ANNs and BNNs 5 suggests a novel possibility of combining their complementary advantages. We thus hypothesized that if the best practices of training ANNs were adapted to train a BNN, then the resultant BNN would be augmented with ANN's advantage of learning from high-dimensional data. In principle, an augmented BNN (ABNN) would be good at learning knowledge from the high-dimensional low-quality life science data and informing better designs of life science data labels ( Figure 1 ).

Here we introduce the first ABNN in life science by training a BNN to learn like an ANN ( Figure 2a and 2b) . Inspired by the fact that larger ANNs almost always perform better 16, 17 , we hypothesized that the largest ABNN could only be attained by limiting team size to one to maximally increase the efficiency of knowledge extraction (Figure 2d ). We adapted the best practices of training ANNs to train a single ABNN that learns from all-encompassing life science data in an uninterrupted pass without imposing interim milestones (Figure 2e ). After eight years of training, the ABNN achieves exponential knowledge extraction from 2000+ life science publications and databases and builds a foundation model 6 of human physiology and 130+ specific models of human diseases (Figure 2c ).

We assessed the quality of extracted knowledge in ABNN by measuring to what extent ABNN could increase the productivity in drug discovery. Inspired by the CASP challenge 18 that 3 serves to benchmark ANN performance for protein structure prediction, we designed the public prospective prediction of pivotal ongoing clinical trial outcomes at large scale (PROTOCOLS) challenge to benchmark ABNN performance for drug efficacy prediction (Figure 3a and Methods section 'Validation design').

The rationale of the PROTOCOLS challenge is that pivotal clinical trials (phase 2 and phase 3) are statistically powered to evaluate drug clinical efficacy preordained mainly by the underlying biological processes that can be distilled into scientific knowledge. Historical clinical success rates for investigational drugs are well-curated and duly updated 8, 19 to provide an accurate baseline for evaluating ABNN performance in the PROTOCOLS challenge.

The PROTOCOLS challenge evaluated the real-world performance of ABNN in actual clinical settings with an emphasis on the generalizability of ABNN to novel drug-disease pairs even with scarce or uninformative prior clinical data ( Figure 3b ). Therefore, there would be no gap between the validation performance of ABNN in the PROTOCOLS challenge and the clinical utility of ABNN in real-world drug discovery 20,21 .

The PROTOCOLS validation consists of 265 then-ongoing pivotal clinical trials following a predefined set of screening criteria (Figure 3c and Methods section 'Validation data collection').

The sample of validation clinical trials and the sample of newly initiated clinical trials since 4 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 15, 2022. ;  https://doi.org/10.1101/2022.03.14.22272372 doi: medRxiv preprint 2020 are shown to follow identical distribution across all major therapeutic areas (two-sample Kolmogorov-Smirnov test, statistic = 0.333; P = 0.73; Figure 4 ). The PROTOCOLS validation could thus provide an unbiased evaluation of ABNN's disease-agnostic performance.

The minimum sample size requirement (131) and the minimum event size requirement (118) were determined for evaluating ABNN's performance with 99% confidence 7 (Figure 3c It should be noted that positive instances (true positive and false negative) are much more important than negative instances (true negative and false positive) in the real-world scenarios of life science and drug discovery. True positives are more interesting than true negatives because the clinical success rates for investigational drugs entering human studies is only 7.9% for all diseases 8 . False positives will only have a marginal clinical impact because human clinical trials will still fail, bringing no clinical harm to patients and only generating the status quo level of sunk R&D costs for drug developers. In contrast, false negatives will have a substantial clinical impact because they deny clinical benefits to patients and eliminate sizable revenue to drug developers that dwarfs saved R&D costs.

Correspondingly, we chose accuracy, F1 score, sensitivity, and specificity as the most appro-5 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 15, 2022. ;  https://doi.org/10.1101/2022.03.14.22272372 doi: medRxiv preprint priate performance measures for the PROTOCOLS validation 22 . We also reported other standard measures to offer a balanced view of ABNN's performance (Data Table 2 ).

As ABNN was trained to functionally reconstruct human physiology and almost all major diseases that could possibly occur to human body (see Methods section 'Model training'), we first evaluate ABNN's disease-agnostic performance for the full validation dataset (158 predictions;

Supplementary Table 1 ). ABNN achieved 82.9% prospective prediction accuracy (99% CI 74.3%, 89.9%; P < 0.0001), a nearly 10.5-fold improvement from the realistic baseline accuracy of 7.9% and an almost 5.5-fold improvement from the conservative baseline accuracy of 15.1% (Figure 5a ;

Methods section 'Baseline performance'). ABNN achieved 0.86 F1 score (99% CI 0.79, 0.92; P < 0.0001; Figure 6c ; Data Table 1 )., 90.2% sensitivity (99% CI 80.2%, 96.9%; P < 0.001; Figure 6b ; Data Table 1 ) and 72.7% specificity (99% CI 57.5%, 85.3%; P < 0.0001; Figure 6b ; Data Table   1 ). Those data clearly demonstrate that ABNN has extracted large-scale high-quality knowledge to enable its superb disease-agnostic performance in the PROTOCOLS validation.

As ABNN does not require prior clinical data to predict investigational drugs' clinical efficacy (Figure 3a ), we conduct a couple of further analyses for subgroups of the validation dataset with varying degrees of reduced availability of prior clinical data.

First-in-class clinical trials for novel drug-disease pairs represent the most challenging subset of the PROTOCOLS validation because no prior clinical data are available for those drug-disease pairs across all therapeutic areas. As there are 128 first-in-class clinical trials in the validation dataset, the minimum sample size and event size requirements for 99% confidence have been met.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 15, 2022 Figure 6b ) and 71.7% specificity (99% CI 55.6%, 85.0%; P < 0.0001; Data Table 1 ; Figure 6b ).

ABNN's performance for first-in-class clinical trials is shown to be non-inferior over its performance for all validation clinical trials (∆ = 0.4%; 99% CI -0.95%, 1.75%; P < 0.0001 for non-inferiority at a 2% margin; Figure 5b ; Methods section 'Statistical analysis'). Notably, ABNN showed superior disease-agnostic sensitivity for first-in-class clinical trials to that for all clinical trials (∆ = 2.2%; 99% CI -0.95%, 5.35%; P < 0.002 for superiority at a 2% margin; Methods section 'Statistical analysis'). Our results clearly demonstrate that ABNN's superb performance in the PROTOCOLS validation is independent of the availability of prior clinical data for any drug-disease pair.

Oncology clinical trials represent a different type of challenge for ABNN because they have the lowest historical clinical success rates: The realistic baseline accuracy is 5.3% for oncology and 23.9% for hematology 8 (Methods section 'Baseline performance'). Consequentially, the importance of already preferred positive instances is even higher in oncology than in other therapeutic areas, to the reasonable extent that negative instances are no longer interesting. Therefore, a clinically meaningful assessment of ABNN's performance in oncology should primarily focus on F1 score, accuracy, and sensitivity.

Moreover, oncology clinical trials feature the most complex trial designs with active controls 7 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 15, 2022 CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 15, 2022. ;  As there are 49 infectious disease clinical trials in the validation dataset, the minimum sample size and event size requirements for 90% confidence have been met (see Methods section 'Statistical analysis'). 94% (46/49) are COVID-19 pivotal clinical trials that come with neither prior clinical data nor prior life science data (Supplementary Table 4 ).

ABNN achieved 81.6% prospective prediction accuracy (90% CI 70.1%, 88.4%; P < 0.002; Table 1 ) and 88.9% sensitivity (90% CI 68.3%, 95.4%; P < 0.05; Figure   6b ; Data Table 1 ). Those data clearly show that the quality of extracted knowledge in ABNN has Table 2 ) and 0.91 ± 0.10 F1 score (Figure 6c ; Data Table 2 ). Although the minimum requirements for 90% confidence are not met for any of those therapeutic areas (Methods section 'Statistical analysis'), those data demonstrate that ABNN's performance is stable and consistent across all 9 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 15, 2022. ;  https://doi.org/10.1101/2022.03.14.22272372 doi: medRxiv preprint major therapeutic areas in the PROTOCOLS validation.

We also present Alzheimer's Disease (AD) data in the PROTOCOLS validation to demonstrate the robustness of ABNN's extracted knowledge. AD represents an extreme case because the historical clinical success rate of disease-modifying drugs is next to zero 25 . A single hit (true positive) becomes the most appropriate performance measure of ABNN for AD because both false positives and negative instances are equally uninteresting in real-world scenarios. AD thus represents a tough challenge for ABNN because there is a consensus that AD is too complex, the quantity of existing data is too low, and the quality of existing data is too poor 25 . What's worse, existing data are probably more misleading than informative.

ABNN achieved 100% accuracy and 100% precision with non-zero true positive and zero false positive (Supplementary Table 6 ) for three prospective predictions of AD pivotal clinical trials in the PROTOCOLS validation. ABNN's hit is masitinib, a first-in-class c-Kit inhibitor that met the efficacy primary endpoint in the pivotal phase 3 trial (NCT01872598). Our results demonstrate that ABNN has extracted large-scale, high-quality knowledge of AD from existing life science data.

Aging is an evolutionarily conserved phenomenon across all mammalian species 26 and is clinically recognized as the main risk factor of numerous diseases in multiple therapeutic areas 27 .

To evaluate the quality of extracted knowledge about aging in ABNN, we set out to identify all age-related pivotal clinical trials in the PROTOCOLS validation (Methods section 'Validation data collection') and measured ABNN's performance ( Figure 8 ).

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 15, 2022. ;  https://doi.org/10.1101/2022.03.14.22272372 doi: medRxiv preprint

As there are 119 clinical trials of age-related diseases in the validation dataset, the minimum sample size and event size requirements for 99% confidence have been met. ABNN achieved 81.5% prospective prediction accuracy (99% CI 71.3%, 89.7%; P < 0.0001; Data Table 1 ; Figure   9a ), 0.85 F1 score (99% CI 0.76, 0.92; P < 0.0001; Data Table 1 ; Figure 6c )., 91.0% sensitivity (99% CI 79.1%, 98.4%; P < 0.005; Data Table 1 ; Figure 6b ) and 69.2% specificity (99% CI 51.8%, 83.9%; P < 0.0001; Data Table 1 ; Figure 6b ).

ABNN's prospective predictive accuracy for age-related clinical trials is shown to be noninferior over its performance for first-in-class clinical trials (∆ = 1.0%; 99% CI -1.14%, 3.14%; P < 0.0001 for non-inferiority at a 2% margin; Methods section 'Statistical analysis'). Furthermore, ABNN showed non-inferior disease-agnostic sensitivity for all age-related clinical trials to that for all first-in-class clinical trials (∆ = 1.4%; 99% CI -1.12%, 3.92%; P < 0.003 for superiority at a 2% margin; Methods section 'Statistical analysis'). Our results clearly demonstrate that ABNN has extracted sufficient knowledge of aging that significantly contributed to its consistent performance across all the age-related indications in the PROTOCOLS validation ( Figure 9b ). CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 15, 2022. ; https://doi.org/10.1101/2022.03.14.22272372 doi: medRxiv preprint tive knowledge for the corresponding therapeutic areas. ABNN performance is better for the more difficult therapeutic areas (Figure 6d ; Data Table 2 ).

We present the brand-new possibility of deep-learning-augmented human intelligence to build a foundation model of human physiology that enables highly accurate data-free predictions of drug clinical efficacy for almost any human disease. This achievement is intractable for data-driven machine intelligence, whose demand for clinical data is so high and the efficiency of knowledge extraction is so low that the gap between promise and proof becomes nearly unbridgeable ( Figure   1 ).

Humans have designed machine learning methods to train artificial neural networks that have successfully learned black-box models outperforming human experts in playing games 1 and predicting protein structures 2 . Our work shows that machine learning methods can be adapted to train augmented biological neural networks (ABNNs) to successfully learn quasi-white-box models 24 to predict drug clinical efficacy ( Figure 2 ). ABNN could thus safely deliver AI-surpassing clinical utility while averting the numerous challenges in privacy and explainability faced by medical AI systems 21 . ABNN can also inform better design of data labels for training better-performing ANNs with fewer data 13 .

Furthermore, in contrast to domain experts who have privileged access to private data in ad-12 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 15, 2022. ;  dition to public data, ABNN was trained with public data only and started from an underprivileged position. Nonetheless, our ABNN has extracted orders-of-magnitude more knowledge from far less data than experts.

We designed and conducted the most rigorous validation of the quality of extracted knowledge in ABNN: the public, prospective prediction of pivotal ongoing clinical trial outcomes at large scale (PROTOCOLS) challenge ( Figure 3 and Figure 4 ). At 99% confidence, ABNN successfully achieved > 82% prospective prediction accuracy, > 90% sensitivity, and >0.85 F1 score across all therapeutic areas, regardless of the availability of prior clinical data ( Figure 5 and Figure 6 ; Data Table 2 ).

As ABNN takes a drug's mechanism of action and a trial's design protocol as the only inputs for evaluating the clinical efficacy of a novel drug (Figure 3a ), ABNN's performance in the PRO-TOCOLS validation confirms that large-scale, high-quality scientific knowledge alone is sufficient for accurately predicting drug clinical efficacy.

Given that both inputs for ABNN are available before first-in-human studies and positive instances matter much more than negative cases in actual drug discovery and development, ABNN's positive predictions of drug clinical efficacy alone could readily increase the clinical success rates of investigational new drugs from 7.9% 8 to more than 90% and bring a permanent reversal of Eroom's law 4 .

As ABNN is also the world's first clinically validated model of human aging (Figure 8 and

CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 15, 2022. ; Figure 9 ), applying ABNN to cellular rejuvenation programming could substantially speed up the discovery of preventive medicine for age-related diseases 11 .

ABNN also leaves room for improvement as 17.1% (27/158) predictions are false in the PROTOCOLS validation. Further work will be planned to investigate why ABNN performs better for harder diseases. The exponential efficiency of knowledge extraction enables ABNN to translate each false prediction into a substantial improvement of the corresponding disease model. While our ABNN could readily reshape medicine, its bigger impact comes from the training method of ABNNs, which provides a well-beaten path to drastically increase the efficiency of knowledge extraction in every discipline that is characterized by large-scale, low-quality data space (e.g., synthetic biology, material science, and climate science). Our result provides the first positive evidence that the smallest team is necessary for delivering the most disruptive breakthrough, corroborating the previous discovery that small teams disrupt 12 .

The advent of ABNN at the peak of global productivity decline utters in the new era of human-centric AI. The global adoption of training ABNNs will generate a paradigm shift in research culture and organizational structure to mass-produce scientific and technological breakthroughs. ABNNs will give rise to general purpose technologies that could potentially overcome the productivity J-curve and the productivity paradox recurrently observed in the past 28 .

14 .

CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 15, 2022. ; https://doi.org/10.1101/2022.03.14.22272372 doi: medRxiv preprint Validation is critical for an objective assessment of ABNN's general-purpose exponential knowledge extraction from life science data. The most straightforward way is to test to what extent ABNN could reverse Eroom's law, yet it would be unrealistically time-consuming and non-scalable to directly start new drug programs. Running virtual clinical trials is an effective alternative: Using drug mechanism of action and clinical trial design protocol as the only inputs, ABNN would predict new drug clinical efficacy using extracted knowledge only without access to patient data or thirdparty confidential information. Highly accurate virtual clinical trials could be run before first-inhuman studies and prevent drug developers from starting pivotal real-world trials that are doomed to failure 29 .

To meet the stringent criteria of the PROTOCOLS challenge as shown in Figure 3b , the most rigorous validation of ABNN would be to publish prospective predictions of pivotal clinical trial outcomes for all human diseases with tamper-proof timestamps and calculate prediction accuracy with a 99% confidence interval based on the ground truth determined by actual clinical readouts.

There is no selection of lead over nonlead indications, although nonlead indications have far lower success rate 19 .

There are a few hundreds of new pivotal clinical trials whose protocols are publicly accessible in a centralized database as required by FDA 30 and whose clinical readouts are usually published by sponsors in a standardized format. Public, prospective predictions of pivotal ongoing clinical trial outcomes could serve as a validation benchmark for ABNNs as much as ImageNet served as a benchmark validation in visual object recognition for ANNs 31 .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. RBA is not directly available from previous survey studies 8, 19 for two subgroups of the validation datasets: all first-in-class indications (128 trials) and all age-related indications (119 trials).

As diseases in those two subgroups come from therapeutic areas featuring lower-than-average his-17 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 15, 2022. ; https://doi.org/10.1101/2022.03.14.22272372 doi: medRxiv preprint torical clinical success rates (oncology, neurology, cardiovascular, etc.), the real RBAs for both subgroups should be lower than the RBA for all indications (7.9% 8 ). We thus assumed that a reasonable estimate of RBA for the subgroup of all first-in-class indications (128 trials) would be 6.32%, equal to 80% of the RBA for all indications (7.9% 8 ). Adding that no anti-aging therapeutics have ever been clinically approved, we assumed that a reasonable estimate of RBA for the subgroup of all age-related indications (119 trials) would be 5.69%, equal to 72% of the RBA for all indications (7.9% 8 ).

The validation dataset comprises the registration information of human clinical trials on ww w.clinicaltrials.gov with the screening criteria as shown in Figure 3c A clinical trial in the validation dataset is designated as "first-in-class" if the drug-indication pair hasn't been approved for marketing.

A clinical trial in the validation dataset is designated as "age-related" if age is a clinically identified risk factor for the indication thereof.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 15, 2022. ; https://doi.org/10.1101/2022.03.14.22272372 doi: medRxiv preprint

Per the industry-wise best practice 32 , We predict SUCCESS for a pivotal clinical trial if at least one of its prespecified efficacy primary endpoint(s) is believed to be met with predefined statistical significance. ABNN predicts FAILURE for a pivotal clinical trial if none of its prespecified efficacy primary endpoint(s) is believed to be met with predefined statistical significance ( Figure   3d ).

If a pivotal clinical trial has multiple co-primary endpoints, we could predict PARTIAL SUC-CESS, PARTIAL FAILURE if at least one of its prespecified efficacy primary endpoint(s) is believed to be met with predefined statistical significance and at least one of its prespecified efficacy primary endpoint(s) is believed to be not met with predefined statistical significance.

PREDICTION PUBLICATION 265 predictions were published as timestamped tweets @DemiugeTech to establish a publicly accessible track record of prospective predictions. The immutability of tweets ensures that each published prediction cannot be modified afterward. We also indexed each tweet to prevent any intentional deletions of false predictions that go unnoticed to ensure a reliable performance evaluation. Nevertheless, index gaps do exist for several legitimate cases that do not compromise the rigor of validation: a) an index was unnoticedly skipped and remained unused from then on; b) an indexed prediction was made but later became disqualified as a prospective prediction, because the corresponding result had been announced after the indexed prediction was made but before 19 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

It is customary for private companies and mandatory for public companies in the biopharmaceutical industry to forecast the estimated date of clinical readouts and to publish the actual data of clinical readouts for human clinical trials. We track the availability of clinical readouts for every published prospective prediction from multiple online sources, including https://www.g lobenewswire.com/ for press releases, https://www.biospace.com/ for curated news, and financial reports of public companies. We usually published the link to an available clinical readout as a timestamped tweet by replying to the original timestamped tweet of the corresponding prediction, thus illustrating the clearly established timeline of predictions followed by readouts (Figure 3d ).

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 15, 2022. ;  Under the FDA guidelines 33 , a clinical trial with available readout is given the ground-truth label success if and only if at least one efficacy primary endpoint is met according to interim/topline analyses or final data published by the trial sponsors (Figure 3d ).

Similarly, a clinical trial with available readout is given the ground-truth label failure if and only if (1) none of the efficacy primary endpoint(s) is met according to topline analyses or final data or deemed likely to be met according to interim analyses, or (2) the trial is terminated for non-recruitment or non-business reasons, (3) the post-trial development is discontinued for nonbusiness or unspecified reasons, according to the official announcements by the trial sponsors.

Given that the reliability of ground-truth determination is capped by the 85.1% theoretical maximal prediction accuracy of drug clinical efficacy by human clinical trials 34 , we should refrain from directly labeling missed predictions as false without further consideration of subsequent developments. In particular, we should pay attention to missed failure predictions for phase 2b trials that are less statistically powered than phase 3 trials. Missed failure predictions should be more likely to be true rather than false if the trial sponsor decides not to conduct a phase 3 trial for non-business or unspecified reasons.

Compared to the corresponding ground-truth label, a prospective prediction of success is validated as TRUE if its corresponding ground-truth label is also success or invalidated as FALSE if its corresponding ground-truth label is failure. On the other hand, a prospective prediction of 21 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 15, 2022. ; https://doi.org/10.1101/2022.03.14.22272372 doi: medRxiv preprint failure is validated as TRUE if its corresponding ground-truth label is also failure or invalidated as FALSE if its corresponding ground-truth label is success. The confusion matrices of validation performance across on a disease-agnostic basis and on a per-therapeutic-area basis are shown in We make some reasonable assumptions to calculate minimal sample size and minimal event size to detect prediction accuracy, sensitivity, specificity, and F1 score at 99% confidence, using the previously reported method 7 :

The anticipated clinical readout event proportion (ϕ) is set as 0.9 because as of the cutoff date an average of 75% of clinical trials on clinicaltrial.gov report clinical trial results in compliance with the FDAAA 801 and the Final Rule tracked by https://fdaaa.trialstracker.net/, and more than 90% of big-pharma-sponsored clinical trial report results 35 .

The ratio of total observed clinical readout events and total expected clinical readout events (O/E) is set as 1 with a width of 0.15 to account for about 12% of clinical trials that are prematurely terminated without clinical trial results 36 .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 15, 2022. ;  https://doi.org/10.1101/2022.03.14.22272372 doi: medRxiv preprint Accordingly, the minimal sample size requirement is 131 predictions, and the minimal event size requirement is 118 readouts for 99% confidence. From 11. Feb 2020 to 22. Dec 2020, 265 prospective predictions have been published to meet the minimal sample size requirement. By the study cutoff date (March 1, 2022) , 158 clinical readouts (5 phase 1 trials, 69 phase 2 trials, and 85 phase 3 trials) were available (Supplementary Table 1 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 15, 2022. ;  https://doi.org/10.1101/2022.03.14.22272372 doi: medRxiv preprint statistical significance threshold is 0.01.

We used the functions of python SciPy and NumPy libraries.

The raw dataset of the PROTOCOLS validation is publicly available at https://twitter.com/demiur getech.

TBA. 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 15, 2022 . ;

The full information of the PROTOCOLS validation is available in Excel spreadsheets.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 15, 2022 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 15, 2022 . ;

good for low quality data bad for high dimensionality data small-scale knowledge

good for high dimensionality data bad for low quality data low-quality knowledge

Biological systems have intractably many entities at multiple scales.

good for low quality data good for high dimensionality data

The challenge and solution of extracting knowledge from life science data Figure 1 . Biomedical data are difficult to reproduce and hard to structure.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The solo ABNN learning from all datasets should perform orders-of-magnitude better than the team ABNNs each learning from a single dataset. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 15, 2022 

Prospective, not retrospective good for evaluating real-world performance in actual clinical settings. Figure 3b . Prospective validation is much more rigorous than retrospective validation for examining the real-world performance of AI-based systems in actual clinical practices. Large-scale validation is much more rigorous than small-scale validation for enabling an unbiased estimation of the actual predictive power of AI-based systems. E xternal validation using separate datasets independent of the training datasets is much more rigorous than internal validation using held-out portions of the training datasets to evaluate the performance generalizability of AI-based systems to targeted clinical applications. Public validation is much more rigorous than private validation for ruling out all the possibilities of contaminating the performance estimates. Every prospective prediction is published as an indexed tweet that is both timestamped and immutable @DemiurgeTech.

Clinical readouts are usually published as press releases, financial reports, research papers, etc. by trial sponsors.

The ground truth of whether a clinical trial is a success or a failure can be determined directly from clinical readouts.

The prediction is validated (invalidated) as true (false) if it is identical (opposite) to the ground-truth label of the trial. Figure 3d . The workflow of every validation step from start to end (see Methods section for details). To meet the stringent criteria of the PROTOCOLS validation, we used Twitter as the best venue to conduct the PROTOCOLS validation of ABNN with immutable timestamped tweets to build a publicly verifiable track record on the publicly accessible account of @DemiurgeTech. ABNN made prospective predictions of pivotal clinical trial outcomes for all human diseases (except for neurodevelopmental and skeletomuscular rare disorders and hematological disorders). There is no selection of lead over nonlead indications, though nonlead indications have far lower success rate. There are a few hundreds of new pivotal clinical trials whose protocols are publicly accessible in a centralized database as required by FDA and whose clinical readouts are usually published by sponsors in a standardized format. We calculated prediction accuracy with 99% confidence interval based on the ground truth determined by actual clinical readouts. Figure 5a . . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Figure 5c . Table 1 for more details). Figure 6b . Figure 6b . ABNN's performance in terms of sensitivity and 1 -specificity (see Data Table 1 for more details).

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 1 for details). LOA is identical to the realistic baseline accuracy (see Methods section 'Baseline performance'). F1 scores and LOAs across overall validation subgroups are negatively weakly correlated (exact Pearson coefficient = -0.249)

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 15, 2022. ;  https://doi.org/10.1101/2022.03.14.22272372 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 15, 2022. ;  https://doi.org/10.1101/2022.03.14.22272372 doi: medRxiv preprint

Mastering the game of Go with deep neural networks and tree search

Highly accurate protein structure prediction for the human proteome

Biology must generate ideas as well as data

Diagnosing the decline in pharmaceutical R&D efficiency

A deep learning framework for neuroscience

On the opportunities and risks of foundation models

Minimum sample size for external validation of a clinical prediction model with a binary outcome

Clinical Development Success Rates and Contributing Factors

International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

MoA-based Clinical Efficacy Prediction Validation

The AI-discovered aetiology of COVID-19 and rationale of the irinotecan+ etoposide combination therapy for critically ill COVID-19 patients

In vivo partial reprogramming alters age-associated molecular changes during physiological aging in mice

Large teams develop and small teams disrupt science and technology

Learning data-driven curriculum for very deep neural networks on corrupted labels

Cancer reproducibility project yields first results

Make mouse studies work

Language models are few-shot learners

Universal DNA Methylation Age Across Mammalian Tissues

Ageing as a Risk Factor for Disease

The productivity J-curve: How intangibles complement general purpose technologies

An AI boost for clinical trials

ImageNet Large Scale Visual Recognition Challenge

Choosing primary endpoints for clinical trials of health care interventions. Contemp

The Burden of the "False-Negatives" in Clinical Development: Analyses of Current and Alternative Scenarios and Corrective Measures

Compliance with legal requirement to report clinical

 Table 1 . ABNN's primary performance measures.. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)